Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Aug;322(6079):541-4.
doi: 10.1038/322541a0.

Capacity of purified Lyt-2+ T cells to mount primary proliferative and cytotoxic responses to Ia- tumour cells

Capacity of purified Lyt-2+ T cells to mount primary proliferative and cytotoxic responses to Ia- tumour cells

J Sprent et al. Nature. 1986 Aug.

Abstract

Allogeneic gene products of the major histocompatibility complex, the HLA complex in man and the H-2 complex in mice, induce T lymphocytes to exert powerful mixed lymphocyte reactions (MLR) and cell-mediated lympholysis (CML). In mice, the subset of T cells carrying the L3T4 surface antigen but lacking the Lyt-2 antigen responds predominantly to H-2 class II (Ia) differences whereas the L3T4- Lyt-2+ subset reacts to class I (K/D) differences. For primary responses the stimulus for MLR and CML appears to be controlled by Ia+ cells of the macrophage/dendritic cell lineages, for both L3T4+ and Lyt-2+ cells. The finding that Ia+ cells are required for responses involving Lyt-2+ cells has been taken to imply that triggering of these cells is controlled by Ia-restricted L3T4+ cells. Lyt-2+ cells have thus come to be regarded as crippled cells which are heavily dependent on 'help' from other T cells. This well-entrenched view is challenged by evidence presented here that purified Lyt-2+ cells can give high primary responses to certain Ia- tumour cells in vitro.

PubMed Disclaimer

References

    1. Swain SL. Immun. Rev. 1983;74:129–142. doi: 10.1111/j.1600-065X.1983.tb01087.x. - DOI - PubMed
    1. Sprent J, Schaefer M. J. exp. Med. 1985;162:2068–2088. doi: 10.1084/jem.162.6.2068. - DOI - PMC - PubMed
    1. Shreffler DC, David C. Adv. Immun. 1975;20:125–195. doi: 10.1016/S0065-2776(08)60208-4. - DOI - PubMed
    1. Thomas DW, Yamashita U, Shevach EM. Immun. Rev. 1977;35:97–120. doi: 10.1111/j.1600-065X.1977.tb00237.x. - DOI - PubMed
    1. Pettinelli CB, Ahmann GB, Shearer GM. J. Immun. 1980;124:1911–1920. - PubMed

Publication types

Substances